
Payer Evidence Synthesis & HTA Builder
Build evidence-based health technology assessments for payer coverage decisions
What You Can Do
You can structure comprehensive health technology assessments (HTAs) that organize clinical evidence, economic analyses, and regulatory considerations into evidence-based coverage recommendations. This skill helps you synthesize clinical trial data, health economic models, and real-world evidence into clear, defensible payer coverage determinations. You'll generate professional HTA reports that align with major frameworks like ICER, CADTH, and NICE standards.
Features
Organize clinical evidence from trials, observational studies, and meta-analyses into structured summaries with quality assessments and bias evaluation
Build cost-effectiveness models including cost-benefit analysis, budget impact modeling, and cost per QALY calculations with transparent assumptions
Visualize patient treatment pathways and comparators to identify clinical alternatives and positioning within the therapeutic landscape
Structure quantitative and qualitative assessment of therapeutic benefits against safety signals and adverse event data
Cross-reference coverage decisions with FDA approvals, clinical guideline recommendations, and payer-specific policy criteria
Evaluate implications for patients, providers, manufacturers, and plan finances to anticipate coverage challenges
Export professional HTA documents with executive summaries, evidence tables, economic models, and coverage recommendation justifications
Example Output
Example 1: Evidence Summary Table
| Study | Population | Intervention | Comparator | Primary Outcome | Effect Size | Quality |
|---|---|---|---|---|---|---|
| TRIAL-X | N=500, Stage IIIB NSCLC | Drug A + Chemo | Chemo alone | PFS improvement | 4.2 months (HR 0.68) | High |
| TRIAL-Y | N=400, Same indication | Drug B + Chemo | Chemo alone | OS improvement | 7.1 months (HR 0.71) | High |
Example 2: Cost-Effectiveness Model
Base Case (5-year horizon):
- Intervention cost: $285,000
- Comparator cost: $145,000
- Incremental cost: $140,000
- Life-years gained: 0.8
- QALYs gained: 0.65
- Cost per QALY: $215,385 (vs. $150,000 willingness-to-pay threshold)
- Coverage recommendation: Conditional coverage pending value negotiation
Example 3: Coverage Decision Memo Snippet
Recommendation: Approve with prior authorization for [Indication]
- Clinical justification: Statistically significant PFS/OS benefit across subgroups
- Economic justification: Cost-effectiveness acceptable if negotiated to <$150/QALY
- Restriction: Requires oncologist confirmation of Stage IIIB+ disease
- Annual review: Reassess if real-world uptake or safety signals emerge
What's Included
- HTA Template Library: Pre-built templates for drugs, devices, and diagnostics aligned with ICER, CADTH, and NICE methodologies
- Economic Analysis Workbook: Structured models for cost-effectiveness, budget impact, and sensitivity analysis with built-in validation logic
- Evidence Extraction Framework: Systematic processes for identifying bias, extracting data from publications, and creating quality-scored evidence summaries
- Coverage Decision Logic: Decision trees and criteria matrices that map clinical and economic findings to coverage recommendations and restrictions
- Regulatory Cross-Reference Guide: Alignment checklist with FDA approvals, clinical practice guidelines, and major payer policies
- Professional Report Generator: Formats analysis into executive summary, clinical evidence section, economic model detail, and recommendations with justifications
Who It's For
- Payer Medical Directors and P&T Committee Leaders
- Health Economists and Pharmacoeconomics Analysts
- Clinical Pharmacists and Pharmacy & Therapeutics Specialists
- Coverage Policy Managers and Reimbursement Specialists
- Manufacturer HEOR (Health Economics & Outcomes Research) Teams
Best For
- Evaluating new drug or device coverage requests with clinical and economic justification
- Building health economic models and conducting value-based price negotiations
- Creating evidence-based formulary restrictions and prior authorization criteria
- Conducting comparative effectiveness analysis across therapeutic alternatives
- Preparing formal HTA submissions for regulatory or payer review







